Decoding the Combinatorial Epigenetic Information of the Mammalian Genome with Engineered DNA Duplex Readers

Developing and commercializing user-friendly kits for mapping novel CpG duplex modifications to enhance epigenetics research and cancer biomarker discovery.

Subsidie
€ 150.000
2022

Projectdetails

Introduction

In mammalian genomes, epigenetic modifications of the nucleobase cytosine occur in both strands of the DNA duplex in the sequence “CpG”, and they are central regulators of gene expression as well as important cancer biomarkers.

Current Challenges

However, current analytical techniques cannot reveal the combination in which these modifications occur in the two strands of a DNA duplex. The resulting inability to create genomic maps of these “CpG duplex modifications” represents a major roadblock for future developments in epigenetics research and cancer diagnosis.

Project Overview

We have engineered the first affinity enrichment probes for selectively analyzing novel CpG duplex modifications, and integrated them into user-friendly and cost-effective kits for genomic mapping.

Goals

In this project, we will develop and commercialize two kits for mapping the most important novel CpG duplex modifications consisting of:

  1. 5-methylcytosine
  2. 5-hydroxymethylcytosine

These kits will target the epigenetics research and liquid biopsy markets.

Impact

This will provide decisive new impulses for epigenetics research as well as for cancer biomarker discovery and liquid biopsy, both large and rapidly growing markets.

Financiële details & Tijdlijn

Financiële details

Subsidiebedrag€ 150.000
Totale projectbegroting€ 150.000

Tijdlijn

Startdatum1-11-2022
Einddatum30-4-2024
Subsidiejaar2022

Partners & Locaties

Projectpartners

  • TECHNISCHE UNIVERSITAT DORTMUNDpenvoerder

Land(en)

Germany

Vergelijkbare projecten binnen European Research Council

ERC Proof of...

Targeted Microarrays for 5-hydroxymethylcytosine-based Diagnosis of Hematological Malignancies

This project aims to develop a cost-effective DNA chip for mapping 5-hydroxymethylcytosine (5hmC) to identify cancer biomarkers and improve diagnostic testing accessibility.

€ 150.000
ERC Starting...

Comprehensive Platform for the Functional Characterization of Cancer Epigenetics and Diagnosis

EpiCancer aims to develop single-cell epigenetic analysis tools to understand cancer heterogeneity and improve diagnostics through blood tests, enhancing early detection and monitoring of tumors.

€ 1.500.000
ERC Starting...

Towards early cancer detection and tumor classification using epigenomic biomarkers in blood

EpiCblood aims to enhance early cancer detection by increasing cancer-specific cf-nucleosomes through innovative histone modification profiling and computational analysis for improved liquid biopsy assays.

€ 1.499.999
ERC Proof of...

Deep multiplexed epigenetic profiling of plasma cell-free nucleosomes for early cancer diagnostics

This project aims to develop ultra-sensitive methods for detecting histone post-translational modifications in blood plasma to enhance cancer diagnostics and enable universal screening.

€ 150.000
ERC Starting...

Detecting epigenetic biomarkers in the blood for non-invasive precision oncology

Develop new non-invasive diagnostic methods for cancer by analyzing epigenetic markers in circulating tumor DNA to improve sensitivity and monitor disease evolution.

€ 1.500.000